See more : Hollund Industrial Marine, Inc. (HIMR) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmonx Corporation (LUNG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmonx Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Fomento Económico Mexicano, S.A.B. de C.V. (FEMSAUB.MX) Income Statement Analysis – Financial Results
- Spirax-Sarco Engineering plc (SPXSY) Income Statement Analysis – Financial Results
- Arctic Paper S.A. (ATC.WA) Income Statement Analysis – Financial Results
- ZEEKR Intelligent Technology Holding Limited (ZK) Income Statement Analysis – Financial Results
- Indraprastha Medical Corporation Limited (INDRAMEDCO.NS) Income Statement Analysis – Financial Results
Pulmonx Corporation (LUNG)
About Pulmonx Corporation
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 68.68M | 53.66M | 48.42M | 32.73M | 32.60M | 20.00M |
| Cost of Revenue | 17.92M | 13.80M | 12.79M | 11.53M | 10.18M | 7.72M |
| Gross Profit | 50.75M | 39.87M | 35.63M | 21.20M | 22.41M | 12.29M |
| Gross Profit Ratio | 73.90% | 74.29% | 73.59% | 64.77% | 68.77% | 61.42% |
| Research & Development | 18.08M | 15.40M | 13.06M | 7.46M | 6.05M | 6.99M |
| General & Administrative | 89.81M | 77.01M | 64.77M | 44.57M | 34.20M | 20.35M |
| Selling & Marketing | 4.80M | 6.10M | 5.10M | 1.50M | 600.00K | 100.00K |
| SG&A | 94.61M | 83.11M | 69.87M | 46.07M | 34.20M | 20.35M |
| Other Expenses | 0.00 | -396.00K | -585.00K | 3.28M | -617.00K | -916.00K |
| Operating Expenses | 112.69M | 98.50M | 82.93M | 53.53M | 40.25M | 27.34M |
| Cost & Expenses | 130.61M | 112.30M | 95.72M | 65.07M | 50.43M | 35.06M |
| Interest Income | 5.57M | 1.53M | 400.00K | 213.00K | 432.00K | 21.00K |
| Interest Expense | 3.23M | 1.07M | 829.00K | 3.18M | 2.32M | 2.52M |
| Depreciation & Amortization | 1.95M | 4.00M | 3.16M | 400.00K | 1.20M | 270.00K |
| EBITDA | -55.09M | -55.99M | -46.62M | -28.44M | -16.82M | -15.68M |
| EBITDA Ratio | -80.22% | -107.16% | -98.09% | -88.10% | -54.17% | -78.37% |
| Operating Income | -61.94M | -58.64M | -47.30M | -32.33M | -17.84M | -15.05M |
| Operating Income Ratio | -90.19% | -109.27% | -97.70% | -98.77% | -54.73% | -75.24% |
| Total Other Income/Expenses | 1.66M | 67.00K | -1.01M | 314.00K | -2.50M | -3.42M |
| Income Before Tax | -60.27M | -58.57M | -48.32M | -32.02M | -20.34M | -18.47M |
| Income Before Tax Ratio | -87.76% | -109.15% | -99.80% | -97.82% | -62.40% | -92.32% |
| Income Tax Expense | 571.00K | 353.00K | 343.00K | 213.00K | 363.00K | 12.00K |
| Net Income | -60.84M | -58.92M | -48.66M | -32.23M | -20.70M | -18.48M |
| Net Income Ratio | -88.60% | -109.80% | -100.51% | -98.47% | -63.52% | -92.38% |
| EPS | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| EPS Diluted | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| Weighted Avg Shares Out | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
| Weighted Avg Shares Out (Dil) | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx Reports Second Quarter 2024 Financial Results
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
Pulmonx: Low Bar For Q2 Earnings
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
5 Medical Info Systems Stock to Buy for a Stable Portfolio
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Source: https://incomestatements.info
Category: Stock Reports